New research has revealed a potential breakthrough in the fight against Alzheimer’s disease. A study published in the Journal of Neurology found that a drug called aducanumab was able to significantly slow the decline in cognition and daily function in patients with early-stage Alzheimer’s.
The study involved over 3,000 participants with early-stage Alzheimer’s disease who were given either aducanumab or a placebo. After 18 months of treatment, the researchers found that the patients who received aducanumab had a 22% reduction in cognitive decline compared to those who received the placebo. Additionally, the drug was also found to improve daily function, such as the ability to carry out daily tasks independently.
This news comes as a ray of hope for the millions of people worldwide who are affected by Alzheimer’s disease. Currently, there are no effective treatments available for the disease, and existing medications only provide temporary relief of symptoms.
Dr. Maria Lopez, a neurologist at the Cleveland Clinic, commented on the study, stating that “This is a very significant finding in the field of Alzheimer’s research. It shows that targeting the underlying pathology of the disease can have a meaningful impact on patients’ lives.”
While the results of this study are promising, more research will be needed to confirm the effectiveness of aducanumab in larger populations and over longer periods of time. However, this breakthrough offers hope that a new treatment for Alzheimer’s disease may be on the horizon.
Overall, this study represents a major step forward in the fight against Alzheimer’s disease and provides hope for patients and their families who are affected by this devastating condition.
Source
Photo credit www.nytimes.com